Table 2. Prediction of clinicopathologically classified patients by the TACS + TCMF-score.
| Subgroups | Predict grade1 (130) | Predict grade2/3 (413) | OR | P-value | AUC | SEN | SPE |
|---|---|---|---|---|---|---|---|
| Age | |||||||
| ≤50 | 71 (54.6%) | 242 (58.6%) | 2.562 | 7.14E-13 | 0.836 | 0.875 | 0.696 |
| >50 | 59 (45.4%) | 171 (41.4%) | 2.829 | 3.02E-10 | 0.884 | 0.856 | 0.721 |
| Molecular subtype | |||||||
| Luminal A | 41 (31.5%) | 67 (16.2%) | 3.509 | 2.27E-07 | 0.922 | 0.886 | 0.842 |
| Luminal B | 43 (33.1%) | 181 (43.8%) | 2.433 | 6.81E-08 | 0.831 | 0.881 | 0.613 |
| HER2-enriched | 27 (20.8%) | 90 (21.8%) | 2.294 | 6.26E-05 | 0.796 | 0.865 | 0.619 |
| Triple-negative | 19 (14.6%) | 75 (18.2%) | 2.242 | 0.002 | 0.844 | 0.859 | 0.667 |
| Tumor size | |||||||
| ≤2cm | 67 (51.5%) | 151 (36.6%) | 2.592 | 7.08E-10 | 0.841 | 0.817 | 0.667 |
| 2-5cm | 57 (43.8%) | 228 (55.2%) | 2.916 | 3.02E-12 | 0.875 | 0.898 | 0.756 |
| >5cm | 6 (4.6%) | 34 (9.2%) | 1.754 | 0.105 | 0.757 | 0.917 | 0.500 |
| Nodal status | |||||||
| 0 | 74 (56.9%) | 196 (47.5%) | 3.221 | 9.81E-13 | 0.867 | 0.869 | 0.719 |
| 1-3 | 24 (18.5%) | 103 (24.9%) | 2.042 | 3.67E-05 | 0.801 | 0.897 | 0.600 |
| ≥4 | 32 (24.6%) | 114 (27.6%) | 2.680 | 6.77E-06 | 0.897 | 0.855 | 0.800 |